Sign inCreate account

Report workspace tools

NCT04299633COMPLETEDanonymous

A Phase 1, Three-Part, Open-Label Study in Healthy Adult Subjects to Assess the Effect of Phosphate Binders on the Pharmacokinetics of a Single Dose of Vadadustat

Sponsor

Source record

Akebia Therapeutics

Phase

Source record

Phase 1

Modality

AI-normalized

small molecule

Target

AI-normalized

Vadadustat

Indication / condition

AI-normalized

Healthy Volunteers

Intervention

Source record

Vadadustat, Sevelamer carbonate, Calcium acetate, Auryxia®

Source & freshness

Source record

NCT ID

NCT04299633

Original source

ClinicalTrials.gov

Source last updated

Oct 08, 2020

Ingested at

May 31, 2026

Internal sync

Jun 05, 2026

Model version

trialsignal-ai-v1

Normalized confidence

88%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT04299633

Title

A Phase 1, Three-Part, Open-Label Study in Healthy Adult Subjects to Assess the Effect of Phosphate Binders on the Pharmacokinetics of a Single Dose of Vadadustat

Sponsor

Akebia Therapeutics

Status

COMPLETED

Phase

Phase 1

Condition raw

Healthy Volunteers

Condition normalized

Healthy Volunteers

Modality raw

Healthy Volunteers

Modality normalized

small molecule

Target raw

Vadadustat

Target normalized

Vadadustat

Interventions

Vadadustat, Sevelamer carbonate, Calcium acetate, Auryxia®

Public preview

Source record

This clinical trial, sponsored by Akebia Therapeutics, evaluated the pharmacokinetics of Vadadustat when administered with phosphate binders (sevelamer carbonate, calcium acetate, and Auryxia) in healthy adult subjects. The study aimed to understand potential drug interactions that could affect the efficacy and safety of Vadadustat.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

A Phase 1, Three-Part, Open-Label Study in Healthy Adult Subjects to Assess the Effect of Phosphate Binders on the Pharmacokinetics of a Single Dose of Vadadustat

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT04299633

Status

COMPLETED

Phase

Phase 1

Sponsor

Akebia Therapeutics

Executive brief

Investment-Ready Snapshot

This clinical trial, sponsored by Akebia Therapeutics, evaluated the pharmacokinetics of Vadadustat when administered with phosphate binders (sevelamer carbonate, calcium acetate, and Auryxia) in healthy adult subjects. The study aimed to understand potential drug interactions that could affect the efficacy and safety of Vadadustat.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedOct 08, 2020
Internal syncJun 05, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT04299633

Indication

Healthy Volunteers

Modality

small molecule

Target

Vadadustat

Intervention

Vadadustat, Sevelamer carbonate, Calcium acetate, Auryxia®

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.